Univ.-Prof. Mag. Dr. Markus Mitterhauser
Professorship for Applied Diagnostics at the Faculty of Chemistry
Contact Markus Mitterhauser
Curriculum Vitae:
born in Vienna in 1970
1988 Matura at the humanistic high school Kalksburg in Vienna
1989-1996 studied pharmacy at the University of Vienna
1993 diploma thesis at the Karolinska Institute in Stockholm
1994, 1995 research stays at the Chinese University of Hong Kong
1996 Research stay at the Service Hospitalier Frédéric Joliot
Licensed to practice medicine in 1998
1999 Head of the isotope pharmacy at the Vienna General Hospital
2000 Postgraduate course in radiopharmaceutical chemistry and radiopharmacy at ETH Zurich
2003 Dr. rer. nat. at the University of Vienna, then Faculty of Formal and Natural Sciences
Licensed to practice as a hospital pharmacist in 2006
2016 habilitation at the Medical University of Vienna for radiopharmacy
2014,2015, 2019 Visiting Professor for Radiopharmacy and Experimental Nuclear Medicine at the Faculty of Life Sciences at the University of Vienna at the Department of Pharmaceutical Technology
2016-today founding and managing the Ludwig Boltzmann Institute Applied Diagnostics
since January 2022 Professorship for Applied Diagnostics, Faculty of Chemistry at the University of Vienna
Research areas:
* Development of new imaging biomarkers (radiopharmaceuticals) for imaging diagnostics
* Validation of the new imaging biomarkers: in particular with experimental translational methods for translation into clinical applications
* Open Innovation: Involving patients in research at eye level (PPIE)
"Personalized medicine fundamentally benefits from the availability of qualified diagnostic methods. Imaging biomarkers (radiopharmaceuticals) make a contribution to therapy selection, therapy control and prognosis for patients. I would like to make a contribution by providing new tools for this personalized diagnostics by combining different methods for improving personalized medicine at our location.
In addition, it is also necessary not to forget the needs of those affected in this personalized medicine, because only if we understand what the challenges, fears or solutions of those affected are can we conduct targeted research for and with them. Personalized medicine must not stop at the biomarkers, but only where we succeed in using our approach to achieve a lasting positive influence on the quality of life of those affected." (Markus Mitterhauser)